JP2011520868A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011520868A5 JP2011520868A5 JP2011509043A JP2011509043A JP2011520868A5 JP 2011520868 A5 JP2011520868 A5 JP 2011520868A5 JP 2011509043 A JP2011509043 A JP 2011509043A JP 2011509043 A JP2011509043 A JP 2011509043A JP 2011520868 A5 JP2011520868 A5 JP 2011520868A5
- Authority
- JP
- Japan
- Prior art keywords
- ppi
- composition
- low molecular
- stomach
- succinic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 100
- 239000000203 mixture Substances 0.000 claims description 56
- 239000002245 particle Substances 0.000 claims description 50
- 239000001384 succinic acid Substances 0.000 claims description 50
- 150000001735 carboxylic acids Chemical class 0.000 claims description 42
- 210000002784 stomach Anatomy 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 33
- 230000027119 gastric acid secretion Effects 0.000 claims description 30
- 239000002775 capsule Substances 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 9
- 229940126409 proton pump inhibitor Drugs 0.000 claims description 9
- 239000000612 proton pump inhibitor Substances 0.000 claims description 9
- 230000003111 delayed effect Effects 0.000 claims description 8
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 8
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical group O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 6
- 201000000052 gastrinoma Diseases 0.000 claims description 6
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 4
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 208000000718 duodenal ulcer Diseases 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 230000005176 gastrointestinal motility Effects 0.000 claims description 4
- 230000002427 irreversible effect Effects 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 229960000381 omeprazole Drugs 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 2
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 206010019375 Helicobacter infections Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 108010016076 Octreotide Proteins 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 2
- 206010042220 Stress ulcer Diseases 0.000 claims description 2
- 201000008736 Systemic mastocytosis Diseases 0.000 claims description 2
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 claims description 2
- 201000011032 Werner Syndrome Diseases 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 229960000794 baclofen Drugs 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 claims description 2
- 229960005132 cisapride Drugs 0.000 claims description 2
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 229960001253 domperidone Drugs 0.000 claims description 2
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 claims description 2
- 230000002183 duodenal effect Effects 0.000 claims description 2
- 201000006549 dyspepsia Diseases 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- 201000005917 gastric ulcer Diseases 0.000 claims description 2
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 229960004503 metoclopramide Drugs 0.000 claims description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004085 mosapride Drugs 0.000 claims description 2
- 230000000422 nocturnal effect Effects 0.000 claims description 2
- 229960002700 octreotide Drugs 0.000 claims description 2
- 210000001711 oxyntic cell Anatomy 0.000 claims description 2
- 208000000689 peptic esophagitis Diseases 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- -1 small molecule carboxylic acids Chemical class 0.000 claims description 2
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 claims description 2
- 229960002876 tegaserod Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/120,599 US7981908B2 (en) | 2005-05-11 | 2008-05-14 | Compositions and methods for inhibiting gastric acid secretion |
| US12/120,599 | 2008-05-14 | ||
| PCT/IB2009/006176 WO2009138884A2 (en) | 2008-05-14 | 2009-05-14 | Compositions and methods for inhibiting gastric acid secretion |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014194754A Division JP2014240435A (ja) | 2008-05-14 | 2014-09-25 | 胃酸分泌を阻害するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011520868A JP2011520868A (ja) | 2011-07-21 |
| JP2011520868A5 true JP2011520868A5 (enExample) | 2013-04-25 |
Family
ID=41319115
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509043A Withdrawn JP2011520868A (ja) | 2008-05-14 | 2009-05-14 | 胃酸分泌を阻害するための組成物および方法 |
| JP2014194754A Pending JP2014240435A (ja) | 2008-05-14 | 2014-09-25 | 胃酸分泌を阻害するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014194754A Pending JP2014240435A (ja) | 2008-05-14 | 2014-09-25 | 胃酸分泌を阻害するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7981908B2 (enExample) |
| EP (1) | EP2296470A4 (enExample) |
| JP (2) | JP2011520868A (enExample) |
| AU (1) | AU2009247712C1 (enExample) |
| CA (1) | CA2725437C (enExample) |
| IL (1) | IL209296A0 (enExample) |
| WO (1) | WO2009138884A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080020041A1 (en) * | 2004-10-19 | 2008-01-24 | Ayres James W | Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid |
| US7981908B2 (en) * | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
| US7803817B2 (en) | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
| AU2007278986B2 (en) * | 2006-07-25 | 2010-09-16 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI |
| MX368536B (es) | 2013-02-13 | 2019-10-07 | Redhill Biopharma Ltd | Composicion farmaceutica para el tratamiento de helicobacter pylori. |
| CN114315750B (zh) * | 2020-09-29 | 2024-05-10 | 鲁南制药集团股份有限公司 | 一种莫沙必利-丁二酸共晶 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2046334A (en) | 1933-02-25 | 1936-07-07 | Stay On Mfg Company | Utensil |
| US2343011A (en) | 1941-07-11 | 1944-02-29 | Huppert Oskar | Thio-protein plastic |
| SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| JPS59104326A (ja) * | 1982-12-04 | 1984-06-16 | Toyo Jozo Co Ltd | マクロライド抗生物質の安定な経口用製剤および安定化法 |
| SE8301182D0 (sv) | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
| JPS60193917A (ja) | 1984-03-14 | 1985-10-02 | R P Shiila- Kk | 多重構造軟カプセル剤 |
| IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
| JPS6194717A (ja) * | 1984-10-17 | 1986-05-13 | Takara Co Ltd | 合成樹脂製人形等の成形方法およびその装置 |
| US4767627A (en) * | 1985-05-29 | 1988-08-30 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| US5238686A (en) * | 1986-03-27 | 1993-08-24 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| GB8621425D0 (en) | 1986-09-05 | 1986-10-15 | Smith Kline French Lab | Compounds |
| IL88507A (en) | 1987-12-03 | 1993-02-21 | Smithkline Beckman Intercredit | 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them |
| SE8804629D0 (sv) | 1988-12-22 | 1988-12-22 | Ab Haessle | New therapeutically active compounds |
| JP2656338B2 (ja) * | 1989-01-31 | 1997-09-24 | 日東電工株式会社 | 口腔粘膜貼付製剤 |
| CA2015981A1 (en) | 1989-05-10 | 1990-11-10 | Thomas H. Brown | Compounds |
| US5048353A (en) | 1990-03-01 | 1991-09-17 | Beloit Corporation | Method and apparatus for roll profile measurement |
| JPH03287103A (ja) | 1990-04-02 | 1991-12-17 | Seiko Epson Corp | カラーフィルターの形成法 |
| AU649456B2 (en) | 1990-06-20 | 1994-05-26 | Astra Aktiebolag | Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use |
| SE9002206D0 (sv) | 1990-06-20 | 1990-06-20 | Haessle Ab | New compounds |
| US5559152A (en) * | 1992-07-06 | 1996-09-24 | Komissarova; Irina A. | Pharmaceutical composition having antiacoholic activity |
| US7795239B2 (en) | 1992-07-27 | 2010-09-14 | Mueller Medical International LLC | Saccharide compositions and method of use |
| SE9301489D0 (sv) | 1993-04-30 | 1993-04-30 | Ab Astra | Veterinary composition |
| SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| SE9302396D0 (sv) | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
| JP2896532B2 (ja) * | 1994-08-13 | 1999-05-31 | ユーハン コーポレーション | 新規なピリミジン誘導体およびその製造方法 |
| ES2094694B1 (es) * | 1995-02-01 | 1997-12-16 | Esteve Quimica Sa | Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion. |
| SE9500422D0 (sv) * | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
| US6132768A (en) * | 1995-07-05 | 2000-10-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors |
| US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| US5840737A (en) * | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| SE512835C2 (sv) | 1996-01-08 | 2000-05-22 | Astrazeneca Ab | Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare |
| US5677302A (en) * | 1996-02-26 | 1997-10-14 | Apotex Inc. | Thiadiazole compounds useful as proton pump inhibitors |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| US5800832A (en) * | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
| SE9702533D0 (sv) * | 1997-07-01 | 1997-07-01 | Astra Ab | New oral formulation |
| US6296876B1 (en) * | 1997-10-06 | 2001-10-02 | Isa Odidi | Pharmaceutical formulations for acid labile substances |
| US6328993B1 (en) | 1997-12-08 | 2001-12-11 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral administration form for an acid liable active proton pump inhibitor |
| IT1296980B1 (it) * | 1997-12-17 | 1999-08-03 | Istituto Pirri S R L | Capsula doppia come forma farmaceutica per la somministrazione di principi attivi in terapie multiple |
| SE9704870D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
| DE69916273T2 (de) | 1998-06-18 | 2005-05-19 | Vecta Ltd. | Verwendung von gastrin fragmenten oder sythetischen analogen von gastrin zur herstellung eines arzneimittels zur behandlung der helicobacter pylori assozierten störungen |
| SE9902386D0 (sv) | 1999-06-22 | 1999-06-22 | Astra Ab | New formulation |
| US7365047B1 (en) | 1999-09-28 | 2008-04-29 | The Regents Of The University Of California | Use of pentagastrin to inhibit gastric acid secretion or as a diuretic |
| US6228400B1 (en) * | 1999-09-28 | 2001-05-08 | Carlsbad Technology, Inc. | Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same |
| US7429599B2 (en) * | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
| WO2002086504A2 (en) * | 2001-04-24 | 2002-10-31 | Mcgill University | Individualization of therapy with gastroesophageal reflux disease agents |
| US20030235628A1 (en) * | 2001-09-19 | 2003-12-25 | Rajneesh Taneja | Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments |
| US20030175360A1 (en) * | 2002-02-22 | 2003-09-18 | Renzo Luzzatti | Symptomatic relief of gastrointestinal disorders |
| US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| EP1499303A4 (en) * | 2002-04-10 | 2007-07-25 | Fred H Miller | MULTIPHASE MULTI-COMPONENT CAPSULE SYSTEM |
| ATE536887T1 (de) | 2002-06-06 | 2011-12-15 | Univ Washington | Kovalente konjugate zwischen mit artemisinin verwandten endoperoxiden und eisentragenden proteinen und anwendungsverfahren |
| BR0215888A (pt) * | 2002-09-24 | 2005-07-26 | Gumlink As | Goma de mascar compreendendo pelo menos dois diferentes polìmeros biodegradáveis |
| IL152289A0 (en) * | 2002-10-14 | 2003-05-29 | Vectabiotics Ltd | Method and composition for inhibiting h.pylori infection in a mammalian tissue |
| US20060135406A1 (en) * | 2002-10-14 | 2006-06-22 | Sabina Glozman | Compositions and methods for treating pathologies that necessitate suppression of gastric acid secretion |
| AU2003274355A1 (en) * | 2002-10-24 | 2004-05-13 | Micap Plc. | Targeted delivery |
| US6866653B2 (en) * | 2002-10-31 | 2005-03-15 | Kyongtae T. Bae | Method and apparatus for sequential delivery of multiple injectable substances stored in a prefilled syringe |
| GB2394895A (en) | 2002-11-06 | 2004-05-12 | Cipla Ltd | Proton pump inhibitor composition in paste form |
| US20040248942A1 (en) * | 2003-02-20 | 2004-12-09 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| US8802139B2 (en) | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
| CA2536906A1 (en) | 2003-08-27 | 2005-03-10 | Vecta Ltd. | Compositions for treating pathologies that necessitate suppression of gastric acid secretion |
| EP1660052A2 (en) * | 2003-09-03 | 2006-05-31 | Agi Therapeutics Limited | Proton pump inhibitor formulations, and methods of preparing and using such formulations |
| US7211568B2 (en) * | 2003-12-18 | 2007-05-01 | Kosan Biosciences Incorporated | 9-Desoxoerythromycin compounds as prokinetic agents |
| BRPI0506704A (pt) | 2004-01-06 | 2007-05-02 | Panacea Biotec Ltd | composições farmacêuticas compreendendo inibidor da bomba de prótons e agente pró-cinético |
| US20050181052A1 (en) * | 2004-02-17 | 2005-08-18 | Patel Satishkumar A. | Lansoprazole microtablets |
| WO2005117870A2 (en) * | 2004-04-16 | 2005-12-15 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and prokinetic agent |
| WO2006041942A2 (en) | 2004-10-04 | 2006-04-20 | Qlt Usa, Inc. | Ocular delivery of polymeric delivery formulations |
| ES2525497T3 (es) | 2004-10-08 | 2015-10-09 | Forward Pharma A/S | Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico |
| CA2598696A1 (en) * | 2005-02-23 | 2006-08-31 | Surmodics, Inc. | Implantable medical articles having laminin coatings and methods of use |
| US7981908B2 (en) | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
| US7803817B2 (en) * | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
| PL226695B1 (pl) | 2006-07-03 | 2017-08-31 | Danuta Kruszewska | Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori |
| AU2007278986B2 (en) | 2006-07-25 | 2010-09-16 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI |
-
2008
- 2008-05-14 US US12/120,599 patent/US7981908B2/en not_active Expired - Fee Related
-
2009
- 2009-05-14 EP EP20090746179 patent/EP2296470A4/en not_active Withdrawn
- 2009-05-14 AU AU2009247712A patent/AU2009247712C1/en not_active Ceased
- 2009-05-14 JP JP2011509043A patent/JP2011520868A/ja not_active Withdrawn
- 2009-05-14 US US12/991,746 patent/US9132082B2/en not_active Expired - Fee Related
- 2009-05-14 WO PCT/IB2009/006176 patent/WO2009138884A2/en not_active Ceased
- 2009-05-14 CA CA2725437A patent/CA2725437C/en not_active Expired - Fee Related
-
2010
- 2010-11-14 IL IL209296A patent/IL209296A0/en unknown
-
2011
- 2011-04-19 US US13/089,535 patent/US9370481B2/en not_active Expired - Fee Related
-
2014
- 2014-09-25 JP JP2014194754A patent/JP2014240435A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Maradey-Romero et al. | New and future drug development for gastroesophageal reflux disease | |
| JP2011520868A5 (enExample) | ||
| JP5161071B2 (ja) | 胃酸分泌 | |
| RU2013106514A (ru) | Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи | |
| Scarpignato et al. | the opportunities and benefits of extended acid suppression | |
| ES2376466T3 (es) | Forma de dosificación farmacéutica que comprende peletes, as�? como su procedimiento de fabricación. | |
| CA2605839A1 (en) | Stabilized composition of a proton pump inhibitor | |
| JP2014240435A (ja) | 胃酸分泌を阻害するための組成物および方法 | |
| JP5474541B2 (ja) | 小さいジカルボン酸の誘導体と組み合わせてｐｐｉを用いる胃酸分泌を阻害する組成物および方法 | |
| ES2829285T3 (es) | Administración de AINE y composiciones, métodos y sistemas relacionados | |
| RU2005122465A (ru) | (-)-энантиомер тенатопразола и его применение в терапии | |
| JP2007503427A (ja) | 胃酸分泌の抑制を必要とする病状を治療するための組成物 | |
| US20040082514A1 (en) | Methods for treatment of helicobacter pylori-associated disorders | |
| TW201513895A (zh) | 調配物 | |
| ME00452B (me) | Mikrokapsule za odloženo i kontrolisano oslobadjanje perindoprila | |
| TR201502081A2 (tr) | Antiülseratif farmasötik terkipler. | |
| Sonagre et al. | Current Advances in Technology of Proton Pump Inhibitor Formulations | |
| TR201605487A1 (tr) | Anti̇ülserati̇f farmasöti̇k terki̇pler | |
| TR201503285A2 (tr) | Anti̇ülserati̇f farmasöti̇k terki̇pler | |
| Maradey-Romero et al. | Novel upcoming therapies | |
| TR201511176A2 (tr) | Anti̇ülserati̇f farmasöti̇k terki̇pler | |
| TR201606324A1 (tr) | Anti̇ülserati̇f farmasöti̇k terki̇pler | |
| TR201604058A1 (tr) | Oral terapöti̇k formülasyonlar | |
| TR201605072A1 (tr) | Anti̇ülserati̇f farmasöti̇k terki̇pler |